Novo Nordisk CFO Said In Active Dialogue With Antitrust Regulators Over Catalent Deal, Still Expects It To Close Toward End Of Year -Conf Call
Portfolio Pulse from charles@benzinga.com
Novo Nordisk's CFO announced that the company is in active discussions with antitrust regulators regarding its deal with Catalent. Despite these discussions, Novo Nordisk still expects the deal to close by the end of the year.
August 07, 2024 | 11:41 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Catalent is involved in a deal with Novo Nordisk, which is currently under review by antitrust regulators. The deal is still expected to close by the end of the year.
The antitrust review introduces some uncertainty for Catalent, but the expectation that the deal will close by year-end provides a neutral short-term outlook for Catalent's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
Novo Nordisk is in active discussions with antitrust regulators about its deal with Catalent, but still expects the deal to close by the end of the year.
The ongoing discussions with antitrust regulators introduce some uncertainty, but the expectation that the deal will close by year-end provides a neutral short-term outlook for Novo Nordisk's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100